Argent BioPharma Dirección

Dirección controles de criterios 3/4

El CEO de Argent BioPharma es Roby Zomer , nombrado en Feb 2016, tiene una permanencia de 8.75 años. compensación anual total es A$417.06K, compuesta por 92.8% salario y 7.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 17.12% de las acciones de la empresa, por valor de €1.38M. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 3.9 años, respectivamente.

Información clave

Roby Zomer

Chief Executive Officer (CEO)

AU$417.1k

Compensación total

Porcentaje del salario del CEO	92.8%
Permanencia del CEO	8.8yrs
Participación del CEO	17.1%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	3.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Roby Zomer en comparación con los beneficios de Argent BioPharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	AU$417k	AU$387k	-AU$18m
Mar 31 2024	n/a	n/a	-AU$17m
Dec 31 2023	n/a	n/a	-AU$17m
Sep 30 2023	n/a	n/a	-AU$19m
Jun 30 2023	AU$354k	AU$354k	-AU$21m
Mar 31 2023	n/a	n/a	-AU$22m
Dec 31 2022	n/a	n/a	-AU$23m
Sep 30 2022	n/a	n/a	-AU$22m
Jun 30 2022	AU$629k	AU$422k	-AU$20m
Mar 31 2022	n/a	n/a	-AU$19m
Dec 31 2021	n/a	n/a	-AU$18m
Sep 30 2021	n/a	n/a	-AU$17m
Jun 30 2021	AU$481k	AU$281k	-AU$16m
Dec 31 2020	n/a	n/a	-AU$13m
Sep 30 2020	n/a	n/a	-AU$16m
Jun 30 2020	AU$440k	AU$290k	-AU$19m
Dec 31 2019	n/a	n/a	-AU$18m
Sep 30 2019	n/a	n/a	-AU$14m
Jun 30 2019	AU$495k	AU$330k	-AU$11m
Dec 31 2018	n/a	n/a	-AU$7m
Sep 30 2018	n/a	n/a	-AU$7m
Jun 30 2018	AU$498k	AU$334k	-AU$8m

Compensación vs. Mercado: La compensación total de Roby($USD269.51K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD474.54K).

Compensación vs. Ingresos: La compensación de Roby ha aumentado mientras la empresa no es rentable.

CEO

Roby Zomer (44 yo)

8.8yrs

Permanencia

AU$417,064

Compensación

Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Roby Zomer	Co-Founder	8.8yrs	AU$417.06k	17.12% € 1.4m
Igor Bluvstein	Chief Financial Officer	less than a year	sin datos	sin datos
Yifat Steuer	Deputy CEO & COO	2.1yrs	sin datos	2.06% € 165.4k
Shachar Shimony	Group General Counsel	no data	sin datos	sin datos
Masa Oblak	People Manager	no data	sin datos	sin datos
Amir Polak	Chief Pharmaceutical Development Officer	no data	sin datos	1.09% € 87.7k
Sabina Suljakovic	Chief Quality and Commercial Officer	4.2yrs	sin datos	sin datos
Nadya Lisovoder	Chief Medical Officer	no data	sin datos	sin datos
Sasha Friedman	Deputy CEO	no data	sin datos	sin datos
Yair Tal	Chief Information Security Officer	no data	sin datos	sin datos
Rowan Harland	Company Secretary	1.7yrs	sin datos	sin datos
Ana Oblak	Group Financial Controller	no data	sin datos	sin datos

2.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de H5O0 se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Roby Zomer	Co-Founder	8.8yrs	AU$417.06k	17.12% € 1.4m
Ross Grant Walker	Chairman of Strategic Advisory Board	no data	AU$32.00k	sin datos
Uri Kramer	Member of Strategic Advisory Board	8.3yrs	sin datos	sin datos
Layton Mills	Independent Non-Executive Director	1.4yrs	AU$61.92k	sin datos
Wendyl D'Souza	Member of Medical Advisory Board	6.3yrs	sin datos	sin datos
Daniel Robinson	Non-Executive Director	less than a year	AU$41.92k	sin datos
Shlomo Sadoun	Member of Advisory Board	less than a year	sin datos	sin datos

3.9yrs

Permanencia media

Junta con experiencia: La junta directiva de H5O0 se considera experimentada (3.9 años de antigüedad promedio).

Argent BioPharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Co-Founder recently bought €1.0m worth of stock

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Less than half of directors are independent

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

Less than half of directors are independent

Recent updates

Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Co-Founder recently bought €1.0m worth of stock

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Less than half of directors are independent

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

Less than half of directors are independent

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

First half 2022 earnings: EPS in line with expectations, revenues disappoint

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding

Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil

Full year 2021 earnings released: AU$0.007 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System